Title |
Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
|
---|---|
Published in |
Oncolytic Virotherapy, October 2016
|
DOI | 10.2147/ov.s99532 |
Pubmed ID | |
Authors |
Marlana Orloff |
Abstract |
On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US Food and Drug Administration approval for the treatment of melanoma in the skin and lymph nodes. Its approval has added yet another therapeutic option to the growing list of effective therapies for melanoma. Though the Phase III OPTiM trial has demonstrated its efficacy as a single agent, the target patient population remains narrow. With numerous effective and tolerable treatments available for unresectable and metastatic melanoma, intralesional therapies such as T-VEC are still finding their niche. T-VEC is now widely accepted as option for treatment; however, its combination with various other agents in an effort to expand its use and synergize with other interventions is still being explored. This article will review the pre-clinical and clinical work that eventually led to the Food and Drug Administration approval of this first-in-class agent, as well as address concerns about clinical application and ongoing research. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 40 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 8 | 20% |
Student > Ph. D. Student | 8 | 20% |
Researcher | 7 | 18% |
Student > Master | 5 | 13% |
Other | 2 | 5% |
Other | 3 | 8% |
Unknown | 7 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 28% |
Biochemistry, Genetics and Molecular Biology | 9 | 23% |
Agricultural and Biological Sciences | 7 | 18% |
Immunology and Microbiology | 3 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
Other | 2 | 5% |
Unknown | 6 | 15% |